Monday Morning Optimism

A miracle treatment for cystic fibrosis

This post is sponsored by Suited, a digital marketing firm that recently redesigned the Sage Policy Group website (check it out, it’s gorgeous) and has been helping our small business with marketing and branding. Suited, much like Sage, works with clients in all segments but is especially experienced in the construction industry. If you’re in the market for a new website or need help with marketing, branding, IT, or anything else digital, we strongly urge you to reach out to them.

About 2,500 children are born with cystic fibrosis in the U.S. every year. Five years ago, those children would have had an expected lifespan of roughly 35 years, and that was with the most cutting edge treatments; 50 years ago, a baby born with CF could expect to live to age 10.

That was before Trikafta, a treatment approved in late 2019 that is projected to extend a patient’s lifespan to 82.5 years (if initiated at a young age). For the 40,000 people living in America with CF, this is an absolute miracle.

Beyond the incredible 135% increase in expected lifespan, those taking Trikafta experience a profound improvement in their quality of life—like this woman who went from 65% pulmonary function to 85% in about two months and ran a half marathon within a year, or this woman who was able to complete a marathon after three failed attempts prior to Trikafta.

What’s Next

This week is all about Wednesday’s consumer price index release, which will hopefully give us yet another reason for optimism. We’ll cover that and more in our Week in Review post on Friday.